IV dexamethasone

Phase 2Small molecule

UUniversity Health Network, Toronto

IV dexamethasone is one of 19 small molecule programs targeting COVID-19. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

COVID-19Active, not recruiting

COVID-19Phase 2

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Singulair

AstraZeneca

Preclinical

1 2

Activella

Eli Lilly

Preclinical

—3

Proventil

Mylan Pharmaceuticals Inc

Preclinical

1 4

Nitrostat

VViatris Specialty LLC

Preclinical

1 5

SARS-COV-2 VACCINE

Moderna

Preclinical

2 6

Achromycin V

WWyeth-Lederle Vaccines

Statins

1 8

IV dexamethasone

UUniversity Health Network, Toronto

Phase 2

1 9

Antihypertensive Agents

NNational Heart, Lung, and Blood Institute (NHLBI)

Preclinical

1 10

Conventional

PPopulation Health Research Institute

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

N/ANot yet recruiting

Dexamethasone

NCT07474909

Clinical

Trials by Indication[1]

Dexamethasone2 trials

Comparison of Analgesic Consumption Between Perioperative ıv Dexamethasone and Added to Femoral Block

Unknown status·TTC Erciyes University·Phase 4·NCT02090790·60 enrolled

Perineural vs Intravenous Dexamethasone as an Adjuvant to Brachial Plexus Block in Pediatric Hand Surgery

Not yet recruiting·PPoznan University of Medical Sciences·N/A·NCT07474909·150 enrolled

Tonsillectomy1 trial

Effect of Steroids on Post-tonsillectomy Morbidities

Completed·KKing Fahd General Hospital·Phase 2·NCT02401529·100 enrolled

COVID-191 trial

Randomized Clinical Trial of Intranasal Dexamethasone as an Adjuvant in Patients With COVID-19

Completed·EEdda Sciutto Conde·Phase 2·NCT04513184·66 enrolled

Neuromuscular Block1 trial

Impact of iv Dexamethasone on Reversal of Rocuronium-induced Neuromuscular Block by Sugammadex

Withdrawn·—·Phase 4·NCT02562417

Peripheral Nerve Block1 trial

IV Dexamethasone for Prolongation of Peripheral Nerve Block

Completed·UUniversity Health Network, Toronto·Phase 3·NCT02864602·18 enrolled

2 more indications

Treatment1 trial

Adding a Short Burst of Corticosteroid to the Conventional Treatment of H1 Antihistamines in Emergency Department.

Completed·—·N/A·NCT03296358·75 enrolled

Supraclavicular Brachial Plexus Block1 trial

Intravenous Dexamethasone on Supraclavicular Brachial Plexus Block for Shoulder Arthroscopy

Completed·HHospital for Special Surgery, New York·Phase 4·NCT02688530·140 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for IV dexamethasone. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — IV dexamethasone compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for IV dexamethasone. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Health Network, Toronto company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: UUniversity Health Network, Toronto

IV dexamethasone

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Dexamethasone2 trials

Tonsillectomy1 trial

COVID-191 trial

Neuromuscular Block1 trial

Peripheral Nerve Block1 trial

Treatment1 trial

Supraclavicular Brachial Plexus Block1 trial

References

Drug Info

Quick Facts

Related News